Our business Strategy is based on following strengths and Approvals
US FDA Compliant, TGA, MHRA & ANVISA approved facility with largest capacity of Soft gelatin formulations in India.
Export to Regulated markets- Europe & Australia to drive profits.
Strong R & D Centre – Alliances for NCE Research.
Contract manufacturing capabilities to become a preferred channel partner.
Aggressive marketing strategies and Proficient Customer Services.
In licensing post 2005.
Foray into Biotechnology segment.
Backward Integration into API Manufacturing to capture entire segment of Value Chain.
Strategic Initiatives taken by us
Rapid filing of ANDAs / MAs, DMFs / COSs into US, Europe & Emerging Markets
Expand Custom Research and Manufacturing Support (CRAMS) Services in the Regulated Markets
Acquisitions of growing, profitable pharmaceutical companies and/or products. The company has recently entered into a share purchase agreement with UK's Hale Group to acquire its entire share capital, along with its subsidiary company Bell Sons & Co. The details of the same are given in the Annexure
Commercialize strong pipeline of over 10 new API products
Leverage economies of scale and integrating API and formulation manufacturing
Pursue additional product in-licensing opportunities for domestic markets
Enter into out licensing arrangements with big pharma company in US, Europe to manufacture & market post patent & off patent drugs
Europe, US & Emerging Markets
Become preferred manufacturing partner for large MNC pharma companies by leveraging MPL’s manufacturing infrastructure in API and formulations
Establish a strong presence in the US generic pharmaceutical market through acquisition of a target company to exploit MPL’s low cost API, drug formulation and R&D capabilities
Focus on building IP assets specially in Niche dosage forms
Out-License IP to drive growth / scalability
Build and launch portfolios of generic products in niche segments, technology driven products. In parallel, seek out newer markets with potential
Build significant OTC presence in regulated markets
Integrating & leveraging acquired company strengths to fuel internal growth
India
Become a top 10 fully integrated pharmaceutical company with a diverse portfolio of ethical, branded, generic and OTC products
Continue building presence in speciality markets, including oncology, CNS and biopharmaceuticals
Continue evolution as an innovative developer of patented, NDDS, and in-licensed products (RISUG, GCSF, EGF) and post-patent products
